Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCENDRA HEALTH INC/VA/OMI · Entity 6858 | Director | June 28, 2019 | July 02, 2019 |
| DYNATRONICS CORPDYNT · Entity 73792 | 10% owner | October 30, 2025 | October 30, 2025 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | May 12, 2026 | May 14, 2026 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President and CEO | June 01, 2026 | June 03, 2026 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | January 05, 2023 | February 09, 2023 |
| PIPER SANDLER COMPANIESPIPR · Entity 3863 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCENDRA HEALTH INC/VA/
Report date June 28, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 60,853 |
Reported balance
After 2019-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-28 · Grant · Acquired 48 · Balance 60,853 F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2: Shares acquired through quarterly dividend reinvestment transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d).
F2: Shares acquired through quarterly dividend reinvestment transaction.
DYNATRONICS CORP
Report date October 30, 2025 · Filed October 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,533,824 |
Reported balance
After 2025-10-30 transaction · row 1
1 source rowRow 1 · 2025-10-30 · Other · Acquired 13,405 · Balance 4,533,824 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 891,112 |
Reported balance
After 2025-10-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-10-30 · Other · Acquired 2,690 · Balance 891,112 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25. |
Filing footnotes · ownership attribution and instrument terms
F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.
IDEXX LABORATORIES INC /DE
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11 | Direct | 525 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 234 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 234 · Balance 234 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2034-06-01 | Direct | 705,468 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 705,468 · Balance 705,468 F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 365,297 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 365,297 · Balance 365,297 F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
Orthofix Medical Inc.
Report date January 05, 2023 · Filed February 09, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,966 |
Reported balance
After 2023-01-05 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 14,354 · Balance 205,966 F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3: Includes 14,354 deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders.
F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023.
F3: Includes 14,354 deferred stock units.
PIPER SANDLER COMPANIES
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,575 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,875 · Balance 2,575 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 48,777 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 600 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.17 · Expires 2019-05-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 9,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 5,400 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
SeaSpine Holdings Corp
Report date January 05, 2023 · Filed January 10, 2023
Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-05 transaction · row 1
1 source rowRow 1 · 2023-01-05 · Disposition to issuer · Disposed 460,275 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.68 · Expires 2025-08-01 | Direct | 0 |
Reported balance
After 2023-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-05 · Disposition to issuer · Disposed 98,198 · Balance 0 F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share. F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.18 · Expires 2026-01-01 | Direct | 0 |
Reported balance
After 2023-01-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-05 · Disposition to issuer · Disposed 6,944 · Balance 0 F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share. F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2026-06-07 | Direct | 0 |
Reported balance
After 2023-01-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-05 · Disposition to issuer · Disposed 25,056 · Balance 0 F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share. F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.
F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share.
F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.
F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share.
F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.
F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 1,000 | $16.01 | $16,010.00 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 6 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 16,976 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.07. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 1,000 | $16.01 | $16,010.00 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 5 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Foundation Disclosed balance after: 16,976 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.07. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 10,124 | $16.14 | $163,401.36 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 17,976 F2 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.25. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 10,124 | $16.14 | $163,401.36 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Foundation Disclosed balance after: 17,976 F2 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.25. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 4,450 | $16.01 | $71,244.50 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 28,100 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.05. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 23:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 4,450 | $16.01 | $71,244.50 |
DisclosureSEC source: 0001637761-19-000016 · wf-form4_155009960683652.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Foundation Disclosed balance after: 28,100 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $16.00 to not more than $16.05. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 90 | $207.68 | $18,691.20 |
DisclosureSEC source: 0001567619-19-002176 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 18:23 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 4,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000152 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 76,325 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F1 · balance_after: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F2 · ownership.direct: 25,456 shares of Common Stock held Indirectly by Spouse. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 18:23 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 24,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000152 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,982 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 19:55 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 53 | $6.51 | $345.03 |
DisclosureSEC source: 0000075252-19-000005 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,037 Underlying: Common Stock · 53 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 89 | $210.22 | $18,709.58 |
DisclosureSEC source: 0001567619-18-004940 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 10:55 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 4,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-010788 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 71,381 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F1 · balance_after: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F2 · ownership.direct: 25,456 shares of Common Stock held Indirectly by Spouse. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 10:55 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 21,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-010788 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,356 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 21:24 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 73 | $16.26 | $1,186.98 |
DisclosureSEC source: 0000075252-18-000126 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,984 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:29 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | Exercise / conversionStock Option (right to buy) · Derivative | 43,496 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001637761-18-000127 · wf-form4_153332818344811.xml · derivative · entry 5 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,496 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was immediately exercisable. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:29 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 43,496 | $14.00 | $608,944.00 |
DisclosureSEC source: 0001637761-18-000127 · wf-form4_153332818344811.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,929 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $14.00 to not more than $14.02. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:29 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | Exercise / conversionCommon Stock | 43,496 | $13.60 | $591,545.60 |
DisclosureSEC source: 0001637761-18-000127 · wf-form4_153332818344811.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 79 | $237.76 | $18,783.04 |
DisclosureSEC source: 0001140361-18-034853 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,423 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · derivative · entry 7 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,423 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: 25% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 50,423 | $63.56 | $3,204,764.86 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · nonDerivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $63.50 to $63.625. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 50,423 | $21.12 | $1,064,933.76 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,448 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · derivative · entry 6 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,423 Underlying: Common Stock · 19,448 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: 25% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 19,448 | $63.50 | $1,234,992.73 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $63.50 to $63.55. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:15 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 19,448 | $21.12 | $410,741.76 |
DisclosureSEC source: 0001209191-18-043884 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,353 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001209191-18-043367 · doc4.xml · derivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,871 Underlying: Common Stock · 31,353 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 31,353 | $63.50 | $1,990,981.34 |
DisclosureSEC source: 0001209191-18-043367 · doc4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $63.50 to $63.57. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 31,353 | $21.12 | $662,175.36 |
DisclosureSEC source: 0001209191-18-043367 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,652 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · derivative · entry 7 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,224 Underlying: Common Stock · 39,652 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: 25% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 39,652 | $63.79 | $2,529,401.08 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · nonDerivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $63.50 to $64.44. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 39,652 | $21.12 | $837,450.24 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 120,100 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · derivative · entry 6 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,876 Underlying: Common Stock · 120,100 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · derivative.exercise_date: 25% of the option grant vested on 8/14/2009 (the first anniversary of the grant date of 8/14/2008), and the remaining 75% vested monthly thereafter over 36 months. F5 · balance_after: This stock option was previously reported as covering 130,488 shares of common stock at an exercise price of $42.24 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 120,100 | $64.08 | $7,696,008.00 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $64 to $64.40 Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 120,100 | $21.12 | $2,536,512.00 |
DisclosureSEC source: 0001209191-18-042325 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 13, 2018 19:33 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 4,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-007683 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 67,049 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F1 · balance_after: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F2 · ownership.direct: 25,456 shares of Common Stock held Indirectly by Spouse. Read SEC document |
| July 05, 2018 Filed Jul 13, 2018 19:33 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 21,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-007683 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,776 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:27 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 232 | $16.63 | $3,858.16 |
DisclosureSEC source: 0000075252-18-000108 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,073 Underlying: Common Stock · 232 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| July 02, 2018 Filed Oct 2, 2018 21:16 UTC Amendment | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 70 | $16.63 | $1,164.10 |
DisclosureSEC source: 0000075252-18-000124 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,911 Underlying: Common Stock · 70 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Correction made to the number of phantom shares acquired F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| May 30, 2018 Filed May 31, 2018 20:50 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 7,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-18-000092 · wf-form4_152779973965969.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,929 F2 · shares: The restricted stock award vests as to 25% of the shares subject to the award on the last day of each three-month period of the Reporting Person's continuous service on SeaSpine's board of directors following May 30, 2018. Read SEC document |
| May 30, 2018 Filed May 31, 2018 20:50 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 8,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-18-000092 · wf-form4_152779973965969.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,957 F1 · shares: The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:15 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 10,355 | $16.90 | $174,999.50 |
DisclosureSEC source: 0000075252-18-000088 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,841 Underlying: Common Stock · 10,355 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:47 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031904 · doc4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,919 Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:47 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031904 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,486 Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 2,187 | Not disclosed Strike: $206.62 | Not disclosed |
DisclosureSEC source: 0001140361-18-023099 · doc1.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,187 Underlying: Common Stock · 2,187 shares Expires 2028-05-08 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-023099 · doc1.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464 Underlying: Common Stock · 224 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 08, 2018 Filed May 9, 2018 20:55 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 3,992 | $15.03 | $59,999.76 |
DisclosureSEC source: 0000075252-18-000072 · edgar.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,486 Underlying: Common Stock · 3,992 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:55 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 227 | $15.44 | $3,504.88 |
DisclosureSEC source: 0000075252-18-000072 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494 Underlying: Common Stock · 227 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
| April 30, 2018 Filed May 2, 2018 21:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 96 | $194.49 | $18,671.04 |
DisclosureSEC source: 0001140361-18-021318 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 20:11 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 4,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-003717 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 62,642 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F1 · balance_after: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. F2 · ownership.direct: 25,456 shares of Common Stock held Indirectly by Spouse. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 20:11 UTC | DYNATRONICS CORP DYNT · Entity 73792 | PurchaseCommon Stock | 21,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-003717 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,823 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 22:17 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantPhantom Stock · Derivative | 5 | $15.09 | $75.45 |
DisclosureSEC source: 0000075252-18-000056 · edgar.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267 Underlying: Common Stock · 5 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.